Enumeral Biomedical has signed an oncology-focused collaborative study agreement with Merck.
The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
|Searching for more deal information? Current Partnering offers the following options:
Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved.
Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies